Like the hover boards of the Back to the Future franchise, golden rice is an old idea that looms just beyond the grasp of reality, writes Tom Philpott
Below is an entertaining and incisive article from Tom Philpott on the biotech lobby’s poster child, GM golden rice.
As GMWatch’s Claire Robinson noted recently, golden rice is almost all the biotech lobby has – and, due to the R&D problems laid out below, they don’t even have that.
WTF happened to golden rice?
By Tom Philpott
Mother Jones, Feb 3, 2016
[links to sources are at the URL above]
Like the hover boards of the Back to the Future franchise, golden rice is an old idea that looms just beyond the grasp of reality.
"This Rice Could Save a Million Kids a Year" announced a Time Magazine cover back in 2000. Orange in color, the rice is genetically modified to contain a jolt of beta-carotene, the stuff that gives carrots their hue and that our bodies transform into vitamin A. Diets deficient in that key micronutrient are the leading cause of blindness of children in the global south, where rice tends to be a staple grain. A decade and a half since the Time article, golden rice has yet to be planted commercially—but it continues generating bumper crops of hype. "Is Golden Rice the Future of Food?" the great hipster-foodie journal Lucky Peach wondered last fall, adding that "it might save millions from malnutrition".
If golden rice is such a panacea, why does it flourish only in headlines, far from the farm fields where it's intended to grow? The short answer is that the plant breeders have yet to concoct varieties of it that work as well in the field as existing rice strains. This is made all the more challenging in the face of debates over genetically modified crops and eternal disputes about how they should be regulated.
After seed developers first create a genetically modified strain with the desired trait—in this case, rice with beta carotene—they then start crossing it into varieties that have been shown to perform well in the field. The task is tricky: When you tweak one thing in a genome, such as giving rice the ability to generate beta-carotene, you risk changing other things, like its speed of growth. The Washington University anthropologist and long-time golden rice observer Glenn Stone describes this process as "bringing a superfood down to earth", and it gets little attention in most media accounts.
The most serious effort to commercialize golden rice is centered at the Philippines-based International Rice Research Institute (IRRI), the globe's most prestigious incubator of high-yielding rice varieties. Launched with grants from the Rockefeller and Ford foundations in 1960, IRRI spearheaded the Asian part of what became known as the Green Revolution—the effort to bring US-style industrial agriculture to the developing world. (My review of Nick Cullather's excellent Green Revolution history The Hungry World is here.)
Today, IRRI coordinates the Golden Rice Network and has been working to develop a viable strain since 2006. And so far, it's having trouble. On its website, IRRI reports that in the field latest trials, golden rice varieties "showed that beta carotene was produced at consistently high levels in the grain, and that grain quality was comparable to the conventional variety". However, the website continues, "yields of candidate lines were not consistent across locations and seasons". Translation: The golden rice varieties exhibited what's known in agronomy circles as a "yield drag"—they didn't produce as much rice as the non-GM varieties they'd need to compete with in farm fields. So the IRRI researchers are going back to the drawing board.
Via email, I asked IRRI how that effort is going. "So far, both agronomic and laboratory data look very promising," a spokeswoman replied. But she declined to give a time frame for when IRRI thinks it will have a variety that's ready for prime time. Washington University's Stone says he visited IRRI's campus in the Philippines in the summer of 2015 and heard from researchers that such a breakthrough is "at least several more years" off. The IRRI spokeswoman also declined to comment on Stone's time-frame report.
That's not a very inspiring assessment, given that researchers first successfully inserted the beta-carotene trait in the rice genome in 2000, and that the technology has been lavished with research support ever since—including from the Rockefeller Foundation, the Bill & Melinda Gates Foundation (Grand Challenges in Global Health Initiative), USAID, the Syngenta Foundation, and others, according to the Golden Rice Humanitarian Board.
Of course, among people who think biotechnology has a crucial role to play in solving developing-world malnutrition, IRRI's agronomic struggles are compounded by anti-GMO zealotry as well as what it sees as over-regulation of GMOs in the global south. David Zilberman, an agricultural economist at the University of California at Berkeley, points out that most developing-world nations, including the Philippines, have adopted the Cartagena Protocol on Biosafety, which stipulates a precautionary approach to introducing new GMO products, including restrictions on how trials are conducted. The Cartagena regime stands in sharp contrast to the much more laissez-faire one that holds sway in the United States, Zilberman says.
If the developing world embraced US-style regulation and treated vitamin A deficiency as a medical emergency solvable by golden rice, "it would have become available in 2000" Zilberman says. Based on that premise, he and German agricultural economist Justus Wesseler co-authored a 2014 paper claiming that golden rice has "been available since early 2000" and opposition to it has resulted in "about 1.4 million life years lost over the past decade in India" alone. Such claims abound in pro-GM circles. At a speech at the University of Texas last year, the Nobel laureate British biochemist Sir Richard Roberts accused gold rice opponents of have having committed a "crime against humanity".
To be sure, opposition to golden rice has occasionally gone overboard. In 2013, activists destroyed one of of IRRI's golden rice field trials in the Philippines, for example. "Anti-GMO activism has set back our work, in that we not only concentrate with our research, but we have to also spend time and resources to counter their propaganda," the IRRI spokesperson told me. But the group makes clear that regulation and activism are only two of the challenges facing golden rice—getting it to perform well remains a major task.
Even if and when IRRI does come up with a high-yielding golden rice variety that passes regulatory muster, it remains unclear whether it can actually make a dent in vitamin A deficiency. As the Washington University's Stone notes, vitamin A deficiency often affects people whose diets are also deficient in other vital nutrients. Vitamin A is fat soluble, meaning that it can't be taken up by the body unless it's accompanied by sufficient dietary fat, which isn't delivered in significant quantities by rice, golden or otherwise.
According to Stone, only one feeding study (PDF) has ever showed a powerful uptake of vitamin A by subjects eating golden rice. The paper was much-cited by golden rice proponents, but Stone says it had a major flaw: The subjects were "well-nourished individuals" who already took in sufficient fat in their diets. The study "demonstrated only that Golden Rice worked in children who did not need it," he writes. (The study has since been retracted on claims that the author failed to obtain proper consent from the parents of the participants).
Meanwhile, as IRRI scrambles to perfect golden rice, the prevalence of vitamin A deficiency is declining in the Philippines—according to IRRI itself— from 40 percent of children aged 6 months to 5 years in 2003, to 15.2 percent in 2008. "The exact reasons for these improvements have not been determined, but they may be the results of proven approaches to preventing vitamin A deficiency, such as vitamin A supplementation, dietary diversification, food fortification, and promotion of optimal breastfeeding," the group noted. That drop is part of a long-term trend that involves all of Southeast Asia. According to a 2015 Lancet study funded by the Bill and Melinda Gates Foundation, vitamin A deficiency plagued 39 percent of children in the region in 1991, but only 6 percent in 2013—without the help of golden rice.
But VAD, as the deficiency's known, remains a huge scourge on the Indian sub-continent and in Africa, the study found, affecting more than 40 percent of children in both regions. Whether golden rice will ever help mitigate that ongoing tragedy won't likely be known for some time. But the technology's hardly the slam-dunk panacea its advocates insist it is.